Compare Enveric Biosciences Inc (ENVB) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $122.36. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | QQQE | |
|---|---|---|
Market Cap | $6.20M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $17.40 | $122.72 |
52-Week Low | $1.27 | $96.06 |
Enterprise Value | $1.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
QQQE trades at $121.96, up 1.61% with strong bullish technical signals from moving averages. The equal-weighted Nasdaq-100 ETF offers diversified exposure to large-cap growth stocks, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential Nasdaq-100 inclusion as a catalyst for equal-weighted strategies.
The ETF's equal-weight approach provides defensive positioning amid tech concentration concerns, with recent outperformance driven by mid-tier growth and biotech exposure. Key risks include market volatility and tech sector sensitivity, while institutional interest grows due to balanced Nasdaq exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
